Molecular Profiling of Low‐Grade Appendiceal Mucinous Neoplasms ( LAMN )
Genes, Chromosomes and Cancer · 2024
DOI: 10.1002/gcc.23270 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, 2024. Verfasst von Julia Doll und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, University of Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Appendiceal Neoplasms, Adenocarcinoma, Mucinous, Mutation, Pseudomyxoma Peritonei. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Low‐grade appendiceal mucinous neoplasia (LAMN) represents a relatively rare tumor of the appendix typically diagnosed incidentally through appendectomy for acute appendicitis. In cases where perforation occurs, mucinous content may disseminate into the abdominal cavity, leading to the development of pseudomyxoma peritonei (PMP). The primary objective of this study was to elucidate the molecular characteristics associated with various stages of LAMN and PMP. DNA was extracted from LAMN, primary PMPs, recurrent PMPs, and adenocarcinomas originating from LAMN. The subsequent analysis involved the examination of mutational hotspot regions within 50 cancer‐related genes, covering over 2800 COSMIC mutations, utilizing amplicon‐based next‐generation sequencing (NGS). Our findings revealed activating somatic mutations within the MAPK‐signaling pathway across all tumors examined. Specifically, 98.1% of cases showed mutations in KRAS , while one tumor harbored a BRAF mutation. Additionally, GNAS mutations were identified in 55.8% of tumors, with no significant difference observed between LAMN and PMP. While LAMN rarely displayed additional mutations, 42% of primary PMPs and 60% of recurrent PMPs showed additional mutations. Notably, both adenocarcinomas originating from LAMN showed mutations within TP53 . Furthermore, 7.7% (4/52) of cases exhibited a potentially targetable KRAS G12C mutation. In four patients, NGS analysis was performed on both primary PMP and recurrent PMP/adenocarcinoma samples. While mutations in KRAS and GNAS were detected in almost all samples, 50% of recurrent cases displayed an additional SMAD4 mutation, suggesting a notable alteration during disease progression. Our findings indicate two key points: First, mutations within the MAPK pathway, particularly in KRAS , are evident across all tumors, along with a high frequency of GNAS mutations. Second, progression toward PMP or adenocarcinoma is associated with an accumulation of additional mutations within common oncogenic pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pathology, University of Würzburg, Würzburg, Germany.
- Comprehensive Cancer Center Mainfranken, University of Würzburg Medical Centre, Würzburg, Germany.
- Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery, University Hospital, University of Würzburg, Würzburg, Germany.
- Department of Biochemistry and Molecular Biology, University of Würzburg, Würzburg, Germany.
ORCID-Profile: Armin Wiegering
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Doll, J., Maurus, K., Köhler, F., Matthes, N., Lock, J. F., Germer, C. T., Rosenwald, A., & Wiegering, A. (2024). Molecular Profiling of Low‐Grade Appendiceal Mucinous Neoplasms ( LAMN ). Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.23270
Vancouver
Doll J, Maurus K, Köhler F, Matthes N, Lock JF, Germer CT, et al. Molecular Profiling of Low‐Grade Appendiceal Mucinous Neoplasms ( LAMN ). Genes, Chromosomes and Cancer. 2024. doi:10.1002/gcc.23270
BibTeX
@article{Doll2024,
author = {Doll, Julia and Maurus, Katja and Köhler, Franziska and Matthes, Niels and Lock, Johan F and Germer, Christoph-Thomas and Rosenwald, Andreas and Wiegering, Armin},
title = {Molecular Profiling of Low‐Grade Appendiceal Mucinous Neoplasms ( LAMN )},
journal = {Genes, Chromosomes and Cancer},
year = {2024},
doi = {10.1002/gcc.23270}
}
EUVIMED